Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

2/15/24 8:00:00 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $FATE alert in real time by email

SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Monday, February 26, 2024 at 5:00 PM ET to report its fourth quarter and full year 2023 financial results and provide a corporate update.

In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company's effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens, and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:

Christina Tartaglia

Stern Investor Relations, Inc.

212-362-1200

[email protected]

Get the next $FATE alert in real time by email

Date	Price Target	Rating	Analyst
11/18/2024		Underperform → Neutral	BofA Securities
6/17/2024	$4.00 → $6.00	Neutral → Overweight	Piper Sandler
3/27/2023	$6.00	Equal Weight	Wells Fargo
1/24/2023	$115.00 → $7.00	Buy → Neutral	H.C. Wainwright
1/6/2023	$20.00 → $7.00	Outperform → Market Perform	BMO Capital Markets
1/6/2023	$71.00 → $12.00	Overweight → Neutral	Piper Sandler
1/6/2023		Outperform → Market Perform	Cowen
1/6/2023	$107.00 → $5.30	Buy → Hold	Stifel

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Chat with this insight

Recent Analyst Ratings for
$FATE

$FATE
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Redmile Group, Llc sold $573,943 worth of shares (341,633 units at $1.68), bought $668,580 worth of shares (397,964 units at $1.68), disposed of $1,822,692 worth of shares (1,084,936 units at $1.68) and acquired $1,822,692 worth of shares (1,084,936 units at $1.68) (SEC Form 4)

Redmile Group, Llc disposed of $6,157,976 worth of shares (1,655,370 units at $3.72), acquired $6,157,976 worth of shares (1,655,370 units at $3.72) and bought $166,024 worth of shares (44,630 units at $3.72) (SEC Form 4)

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Chat with this insight

Recent Analyst Ratings for $FATE

$FATE Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Redmile Group, Llc sold $573,943 worth of shares (341,633 units at $1.68), bought $668,580 worth of shares (397,964 units at $1.68), disposed of $1,822,692 worth of shares (1,084,936 units at $1.68) and acquired $1,822,692 worth of shares (1,084,936 units at $1.68) (SEC Form 4)

Redmile Group, Llc disposed of $6,157,976 worth of shares (1,655,370 units at $3.72), acquired $6,157,976 worth of shares (1,655,370 units at $3.72) and bought $166,024 worth of shares (44,630 units at $3.72) (SEC Form 4)

Recent Analyst Ratings for
$FATE

$FATE
Insider Purchases